Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia

Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2016.02.027
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pharmacoeconomic Analysis of Dasatinib as a Second-Line Therapy in Patients With Chronic Myelogenous Leukemia

Pharmacoeconomics: theory and practice
2015English

Characteristics of Dasatinib- And Imatinib-Resistant Chronic Myelogenous Leukemia Cells

Clinical Cancer Research
Cancer ResearchOncology
2008English

Increased Cortical Bone Mineralization in Imatinib Treated Patients With Chronic Myelogenous Leukemia

Haematologica
Hematology
2008English

Dasatinib Induces Severe Hemorrhagic Colitis in a Patient With Accelerated Phase of Chronic Myelogenous Leukemia

Korean Journal of Internal Medicine
Internal Medicine
2018English

Long-Term Follow-Up of Lower Dose Dasatinib (50 Mg Daily) as Frontline Therapy in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Cancer
Cancer ResearchOncology
2019English

Impact of Malignant Stem Cell Burden on Therapy Outcome in Newly Diagnosed Chronic Myeloid Leukemia Patients

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2013English

Chronic Myelogenous Leukemia

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2012English

Immunological Studies on Chronic Myelogenous Leukemia

Okayama Igakkai Zasshi (Journal of Okayama Medical Association)
1976English

Protective Autophagy or Autophagic Death: Effects of BEZ235 on Chronic Myelogenous Leukemia

Cancer Management and Research
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy